ImmuCell Corp. (ICCC)
9.84
-0.06
(-0.61%)
USD |
NASDAQ |
Sep 08, 16:00
9.97
+0.13
(+1.32%)
Pre-Market: 20:00
ImmuCell Enterprise Value : 92.96M for Sept. 8, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 08, 2026 | 92.96M |
| September 04, 2026 | 93.50M |
| September 03, 2026 | 94.41M |
| September 02, 2026 | 94.41M |
| September 01, 2026 | 93.68M |
| August 31, 2026 | 92.50M |
| August 28, 2026 | 93.86M |
| August 27, 2026 | 94.59M |
| August 26, 2026 | 94.59M |
| August 25, 2026 | 92.96M |
| August 24, 2026 | 92.96M |
| August 21, 2026 | 94.95M |
| August 20, 2026 | 95.23M |
| August 19, 2026 | 95.59M |
| August 18, 2026 | 92.23M |
| August 17, 2026 | 91.68M |
| August 14, 2026 | 94.86M |
| August 13, 2026 | 102.58M |
| August 12, 2026 | 103.31M |
| August 11, 2026 | 103.04M |
| August 10, 2026 | 103.22M |
| August 07, 2026 | 103.49M |
| August 06, 2026 | 103.67M |
| August 05, 2026 | 101.22M |
| August 04, 2026 | 104.13M |
| Date | Value |
|---|---|
| August 03, 2026 | 103.85M |
| July 31, 2026 | 105.40M |
| July 30, 2026 | 104.04M |
| July 29, 2026 | 103.58M |
| July 28, 2026 | 105.67M |
| July 27, 2026 | 104.67M |
| July 24, 2026 | 103.76M |
| July 23, 2026 | 102.86M |
| July 22, 2026 | 104.67M |
| July 21, 2026 | 105.26M |
| July 20, 2026 | 104.85M |
| July 17, 2026 | 104.63M |
| July 16, 2026 | 104.67M |
| July 15, 2026 | 101.04M |
| July 14, 2026 | 110.03M |
| July 13, 2026 | 104.22M |
| July 10, 2026 | 102.49M |
| July 09, 2026 | 107.62M |
| July 08, 2026 | 100.13M |
| July 07, 2026 | 97.50M |
| July 06, 2026 | 94.95M |
| July 02, 2026 | 97.04M |
| July 01, 2026 | 103.49M |
| June 30, 2026 | 94.86M |
| June 29, 2026 | 95.62M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 3.865B |
| Alnylam Pharmaceuticals, Inc. | 34.46B |
| Anika Therapeutics, Inc. | 268.42M |
| Savara, Inc. | 993.23M |
| Vericel Corp. | 1.932B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 1.835M |
| Revenue (Quarterly) | 7.186M |
| Total Expenses (Quarterly) | 5.352M |
| EPS Diluted (Quarterly) | 0.1996 |
| Gross Profit Margin (Quarterly) | 33.92% |
| Profit Margin (Quarterly) | 25.53% |
| Earnings Yield | 0.85% |
| Operating Earnings Yield | 2.09% |
| Normalized Earnings Yield | 1.401 |